Sign Out
Pregnancy: Pregnancy category D.
Mycophenolate is contraindicated during pregnancy.
Mycophenolate is associated with an increased risk of congenital malformation and first trimester pregnancy loss when used by pregnant women. Females of reproductive potential must be counseled about pregnancy prevention and planning. Advise patients to use acceptable forms of contraception during treatment and for 6 weeks after therapy is discontinued.
Lactation: It is not known if mycophenolate is excreted in human milk. Breastfeeding is not recommended during therapy or for 6 weeks after treatment is complete.
Continue with Google